ADMA Biologics, Inc.
ADMA
$16.91
-$0.77-4.36%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 119.84M | 107.19M | 81.88M | 73.90M | 67.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 119.84M | 107.19M | 81.88M | 73.90M | 67.28M |
| Cost of Revenue | 60.18M | 49.74M | 42.77M | 42.82M | 42.62M |
| Gross Profit | 59.66M | 57.45M | 39.11M | 31.09M | 24.65M |
| SG&A Expenses | 19.58M | 17.55M | 16.64M | 16.22M | 15.19M |
| Depreciation & Amortization | 28.00K | 142.00K | 193.00K | 187.50K | 179.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 80.20M | 67.99M | 60.05M | 59.67M | 58.59M |
| Operating Income | 39.64M | 39.20M | 21.82M | 14.23M | 8.69M |
| Income Before Tax | 36.75M | 35.85M | 18.40M | -17.64M | 2.57M |
| Income Tax Expenses | 840.00K | 3.79M | 595.00K | -- | -- |
| Earnings from Continuing Operations | 35.91M | 32.06M | 17.81M | -17.64M | 2.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.91M | 32.06M | 17.81M | -17.64M | 2.57M |
| EBIT | 39.64M | 39.20M | 21.82M | 14.23M | 8.69M |
| EBITDA | 41.58M | 41.25M | 23.94M | 16.33M | 10.78M |
| EPS Basic | 0.15 | 0.14 | 0.08 | -0.08 | 0.01 |
| Normalized Basic EPS | 0.10 | 0.10 | 0.05 | 0.02 | 0.01 |
| EPS Diluted | 0.15 | 0.13 | 0.08 | -0.08 | 0.01 |
| Normalized Diluted EPS | 0.09 | 0.09 | 0.05 | 0.02 | 0.01 |
| Average Basic Shares Outstanding | 234.57M | 232.42M | 228.87M | 225.97M | 225.28M |
| Average Diluted Shares Outstanding | 244.80M | 242.17M | 236.41M | 225.97M | 233.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
